GSK’s Garnier Touts “Progressive Blockbuster” As Model For Future Drugs
Executive Summary
One way to handle an increasingly cautious FDA would be to take a different tack on development - pursuing "progressive blockbusters" that are approved on a population-by-population basis to prove the drugs are safe in different patient types rather than trying to make a traditional blockbuster big splash, according to GlaxoSmithKline CEO JP Garnier
You may also be interested in...
Wyeth Looks To Specialty Markets As Generics Challenge Current Model
Wyeth's R&D pipeline is evolving the firm toward more specialized areas as several of its blockbuster products face patent expirations and generic challenges
FDA To Review Vytorin Data: ENHANCEd Label To Follow?
FDA expects to complete a review of data from the ENHANCE study for Merck and Schering-Plough's Vytorin within nine months, Office of New Drugs Director John Jenkins announced Jan. 25
GSK Has 25 Potential Launches By Decade’s End; Neuroscience A Focus
GlaxoSmithKline could see 25 new drug launches in the time period from 2007 to 2009, including 12 new chemical entities, eight product line extensions and five vaccines, R&D Chairman Moncef Slaoui stated during a pipeline update with investors Dec. 13 in New York City